Bremelanotide, marketed as Vyleesi, is a novel receptor agonist approved in 2019 by the FDA for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike other treatments, Bremelanotide operates by stimulating neuropeptides associated with arousal, particularly by binding to melanocortin 1 and 4 receptors in the hypothalamus. This action prompts dopamine release, which helps increase sexual desire. Typically taken about 45 minutes before anticipated activity, Bremelanotide has shown promise in boosting sexual interest and reducing distress linked to low desire. Its exact mechanism remains under study, but current findings show it provides an option distinct from flibanserin, enhancing the field of HSDD treatments.
Hall, K. S. K., & Binik, Y. M. (2020). Principles and practice of sex therapy (6th ed.). The Guilford Press.
Paauw, D. (2024). Newer outpatient therapies and treatments, an issue of Medical Clinics of North America. Elsevier.
Stahl, S.M., 2020. Prescriber's Guide: Stahl's Essential Psychopharmacology. United Kingdom: Cambridge University Press.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about PT141 by Euro-Pharmacies, consult with your doctor or healthcare professional.
Stahl, S.M., 2020. Prescriber's Guide: Stahl's Essential Psychopharmacology. United Kingdom: Cambridge University Press.
Stahl, S.M., 2020. Prescriber's Guide: Stahl's Essential Psychopharmacology. United Kingdom: Cambridge University Press.
Stahl, S.M., 2020. Prescriber's Guide: Stahl's Essential Psychopharmacology. United Kingdom: Cambridge University Press.
Home
